EyePoint Pharmaceuticals

76 articles with EyePoint Pharmaceuticals

• EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®

  12/7/2021

  EyePoint Pharmaceuticals, Inc. and ImprimisRx jointly announced the expansion of their commercial alliance in which ImprimisRx will assume responsibility for U.S. sales and marketing activities for DEXYCU® 9% for the treatment of post-operative inflammation following ocular surgery in the U.S.

• EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering

  11/19/2021

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), today announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock.

• EyePoint Pharmaceuticals Announces Pricing of Public Offering - Nov 17, 2021

  11/17/2021

  EyePoint Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 4,027,273 shares of its common stock at a public offering price of $13.75 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock at a price to the public of $13.74 per each pre-funded warrant.

• EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - Nov 16, 2021

  11/16/2021

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.

• EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

  11/13/2021

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced six-month interim data from the "Durasert® and Vorolanib in Ophthalmology" Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor treatment targeting wet age-related macular degeneration.

• EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - Nov 11, 2021

  11/11/2021

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at two upcoming virtual conferences:

• EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD

  11/5/2021

  EyePoint Pharmaceuticals, Inc. today announced that management will host a conference call to highlight interim data from its ongoing Phase 1 DAVIO trial of EYP-1901 for the potential treatment of wet AMD on Saturday, November 13 at 12:00 P.M. ET/11:00 A.M. CST.

• EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

  11/3/2021

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced financial results for the third quarter ended September 30, 2021 and highlighted recent corporate developments.

• EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer

  11/1/2021

  EyePoint Pharmaceuticals, Inc. today announced the appointment of Jay S. Duker, M.D. as Chief Operating Officer (COO).

• EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021

  10/27/2021

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 3, 2021 to report its third quarter 2021 financial results and discuss recent business highlights.

• 

  Clinical Catch-Up: October 11-15

  10/18/2021

  It was yet another busy week for clinical trial announcements. Take a look.

• EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting

  10/12/2021

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced positive interim safety data from its Phase 1 clinical trial of EYP-1901.

• EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

  9/17/2021

  EyePoint Pharmaceuticals, Inc. announced that a late-breaking abstract highlighting topline data for the Phase 1 DAVIO trial of EYP-1901 in wet AMD has been selected for presentation at the American Academy of Ophthalmology 2021 Annual Meeting to be held from November 12 – 15, 2021.

• EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - Sep 07, 2021

  9/7/2021

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that EyePoint Pharmaceuticals’ senior management team will present at the following four upcoming conferences.

• EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

  8/10/2021

  EyePoint Pharmaceuticals, Inc. today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C. Wainwright Ophthalmology Virtual Conference being held on August 17, 2021.

• EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

  8/4/2021

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced financial results for the second quarter ended June 30, 2021 and highlighted recent corporate developments.

• EyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board

  8/2/2021

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the formation of its Executive Scientific Advisory Board, chaired by Dr. Carl Regillo M.D., FACS, Chief of the Retina Service at Wills Eye Hospital.

• EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021

  7/28/2021

  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 4, 2021 to report its second quarter 2021 financial results and discuss recent business highlights.

• EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

  7/20/2021

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that the Company expects to receive a nine month extension on DEXYCU®’s pass-through payment status, which otherwise would expire on March 31, 2022.

• EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD

  7/6/2021

  EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced positive safety results from its Phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration.